X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (554) 554
Book Review (135) 135
Publication (55) 55
Newsletter (33) 33
Conference Proceeding (6) 6
Newspaper Article (5) 5
Book Chapter (4) 4
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
vandetanib (539) 539
index medicus (342) 342
humans (305) 305
oncology (233) 233
cancer (159) 159
double-blind (124) 124
thyroid cancer (124) 124
tyrosine kinase inhibitor (111) 111
female (107) 107
sorafenib (107) 107
male (103) 103
antineoplastic agents - therapeutic use (102) 102
lung neoplasms - drug therapy (92) 92
middle aged (88) 88
carcinoma (87) 87
pharmacology & pharmacy (87) 87
research (86) 86
drug therapy (85) 85
zd6474 (82) 82
chemotherapy (80) 80
care and treatment (79) 79
protein kinase inhibitors - therapeutic use (78) 78
aged (77) 77
animals (77) 77
carcinoma, non-small-cell lung - drug therapy (76) 76
tyrosine kinase inhibitors (75) 75
vascular endothelial growth factor (75) 75
angiogenesis (72) 72
quinazolines - therapeutic use (70) 70
cabozantinib (68) 68
adult (67) 67
bevacizumab (67) 67
piperidines - therapeutic use (67) 67
quinazolines - administration & dosage (65) 65
sunitinib (64) 64
thyroid neoplasms - drug therapy (63) 63
cell lung-cancer (62) 62
piperidines - administration & dosage (62) 62
endothelial growth-factor (60) 60
treatment outcome (59) 59
lung cancer, non-small cell (58) 58
antineoplastic combined chemotherapy protocols - therapeutic use (57) 57
ret (55) 55
disease-free survival (54) 54
phase-ii trial (52) 52
analysis (51) 51
antineoplastic agents - adverse effects (51) 51
egfr (51) 51
quinazolines - adverse effects (51) 51
quinazolines - pharmacology (51) 51
piperidines - adverse effects (50) 50
piperidines - pharmacology (49) 49
phase-ii (48) 48
health aspects (47) 47
inhibitor (47) 47
medullary thyroid cancer (46) 46
tyrosine (46) 46
mice (45) 45
cell line, tumor (44) 44
receptors, vascular endothelial growth factor - antagonists & inhibitors (44) 44
therapy (44) 44
trial (43) 43
growth-factor receptor (42) 42
hematology, oncology and palliative medicine (42) 42
lung cancer (42) 42
medicine & public health (42) 42
antineoplastic agents - pharmacology (41) 41
erlotinib (41) 41
gefitinib (41) 41
protein kinase inhibitors - pharmacology (41) 41
endocrinology & metabolism (40) 40
phase-iii trial (40) 40
article (39) 39
clinical trials (39) 39
medullary thyroid carcinoma (39) 39
metastasis (39) 39
thyroid neoplasms - pathology (39) 39
vegf (39) 39
1st-line treatment (38) 38
mutation (38) 38
protein kinase inhibitors - adverse effects (38) 38
dosage and administration (37) 37
proto-oncogene proteins c-ret - genetics (37) 37
targeted therapy (37) 37
tumors (37) 37
vandetanib plus docetaxel (37) 37
malignant-tumors (35) 35
meta-analysis (34) 34
complications and side effects (33) 33
open-label (32) 32
respiratory system (32) 32
aged, 80 and over (31) 31
epidermal growth factor (31) 31
molecular targeted therapy (31) 31
pharmacology/toxicology (31) 31
receptor, epidermal growth factor - antagonists & inhibitors (31) 31
ret protooncogene (31) 31
angiogenesis inhibitors - therapeutic use (30) 30
antineoplastic agents (30) 30
lung neoplasms - pathology (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (562) 562
French (11) 11
German (8) 8
Japanese (6) 6
Korean (4) 4
Chinese (3) 3
Spanish (3) 3
Italian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, ISSN 1386-1425, 01/2018, Volume 189, pp. 485 - 494
Interaction of an anticancer drug, vandetanib (VDB) with a ligand transporter, lysozyme (LYZ) was explored using multispectroscopic techniques, such as... 
Molecular dynamics | Vandetanib | Vandetanib–lysozyme interaction | Lysozyme | Circular dichroism | ACID | Vandetanib-lysozyme interaction | PROTEIN SECONDARY STRUCTURE | HUMAN SERUM-ALBUMIN | FLAVONOIDS | KINASE INHIBITOR | MOLECULAR DOCKING | CIRCULAR-DICHROISM | FLUORESCENCE | SPECTROSCOPY | FORCE-FIELD | BINDING | Tryptophan | Fluorescence | Hydrogen | Analysis | Protein binding
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 10/2018, Volume 13, Issue 10, pp. 1595 - 1601
Introduction: In ret proto-oncogene (RET)–rearranged lung cancers, data on the frequency of brain metastases and, in particular, the outcomes of multikinase... 
RET rearrangement | RET fusion | vandetanib multikinase inhibitor | brain metastases | lung cancer cabozantinib | TARGETING RET | ONCOLOGY | RESPIRATORY SYSTEM | OPEN-LABEL | PHASE-2 | VANDETANIB
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 11/2019, Volume 181, pp. 111552 - 111552
Tyrosine kinase inhibitors (TKIs) have achieved substantial clinical effects for cancer treatment while causing a number of adverse effects. Since hypoxia is... 
Hypoxia | Vandetanib | 3-Nitro-1,2,4-triazole | Tyrosine kinase inhibitor | VEGFR-2 | EGFR | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 08/2018, Volume 29, Issue 8, pp. 1623 - 1625
Journal Article
Molecular Cancer Research, ISSN 1541-7786, 1901, Volume 17, Issue 3, pp. 751 - 760
Medullary thyroid carcinoma (MTC) originates from the C cells of the thyroid gland, which secrete calcitonin. Lymph node and distant metastases are frequently... 
CABOZANTINIB | ONCOLOGY | PATHWAY | DEGRADATION | PROLIFERATION | VANDETANIB | MECHANISMS | TRANSCRIPTION FACTOR | RET PROTOONCOGENE | CELL BIOLOGY
Journal Article
Dermatologic Therapy, ISSN 1396-0296, 09/2010, Volume 23, Issue 5, pp. 553 - 555
Journal Article
American Journal of Clinical Oncology: Cancer Clinical Trials, ISSN 0277-3732, 2017, Volume 40, Issue 4, pp. 393 - 398
Journal Article
Medicine, ISSN 0025-7974, 08/2019, Volume 98, Issue 31, pp. e16392 - e16392
Byline: Yue Yin, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pharmacy; Xin Ye Qiu, Beijing Youan... 
Medicine, Experimental | Medical research | Vandetanib | Care and treatment | Dosage and administration | Thyroid cancer | Index Medicus | Abridged Index Medicus
Journal Article
CORNEA, ISSN 0277-3740, 06/2018, Volume 37, Issue 6, pp. 789 - 792
Purpose: To report 2 cases of cornea verticillata (CV) after vandetanib treatment for medullary thyroid carcinoma (MTC). Methods: In this retrospective... 
GROWTH-FACTOR RECEPTOR | vandetanib | confocal microscopy | cornea verticillata | OPHTHALMOLOGY | AMIODARONE KERATOPATHY | EGFR
Journal Article
Medicine (United States), ISSN 0025-7974, 10/2017, Volume 96, Issue 43
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 08/2019, Volume 136, pp. 104943 - 104943
Drug-eluting Embolic Bead - Transarterial Chemoembolisation (DEB-TACE) is a minimally invasive embolising treatment for liver tumours that allows local release... 
Chemoembolisation | Vandetanib | Drug delivery | Drug-eluting beads | IVIVC | DOXORUBICIN | TRANSARTERIAL CHEMOEMBOLIZATION | RADIOPAQUE BEADS | DC BEAD | PHARMACOLOGY & PHARMACY | VIVO PHARMACOKINETICS
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2018, Volume 29, Issue 6, pp. 1340 - 1343
Journal Article
Endocrine, ISSN 1355-008X, 02/2019, Volume 63, Issue 2, p. 293
Eighteen patients with progressive MTC underwent baseline 18.sup.F-FDG PET/CT prior to and 3 months after vandetanib initiation. By manual segmentation of the... 
Vandetanib | Cancer patients | Usage | Thyroid cancer | PET imaging | Dosage and administration | Research | Drug therapy | Health aspects
Journal Article
Oncotarget, ISSN 1949-2553, 12/2018, Volume 9, Issue 102, pp. 37662 - 37675
Medullary thyroid carcinoma (MTC) is a slow growing neuroendocrine (NE) tumor for which few treatment options are available. Its incidence is rising and... 
Animal model | Vandetanib | Targeted therapy | Medullary thyroid carcinoma | Tyrosine kinase inhibitors
Journal Article
EUROPEAN JOURNAL OF ENDOCRINOLOGY, ISSN 0804-4643, 05/2015, Volume 172, Issue 5, pp. R215 - R225
Context: Many tyrosine kinase inhibitors (TKIs) have been studied in patients with thyroid carcinoma (TC). However, the effect and toxicity of various TKIs in... 
FDG-PET | PHASE-II TRIAL | SOLID TUMORS | EFFICACY | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | CANCER STATISTICS | VANDETANIB | QUALITY-OF-LIFE | SORAFENIB | ADVERSE EVENTS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2017, Volume 35, Issue 13, pp. 1403 - 1410
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 09/2018, Volume 7, Issue Suppl 3, pp. S218 - S220
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.